Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FORGOTTEN HISTORY: Obesity news topic - The Untold Story

Ozempic Changed Obesity Treatment Forever — but Experts See a Bigger Medical Revolution Still Coming

A June 20, 2026 ScienceDaily report on a Gastroenterology commentary describes how GLP-1 drugs opened the door to a next era combining drugs, minimally invasive procedures, and precision medicine.

Medical Daily

Kids as young as six are being given weight-loss drugs as a way to curb obesity before it gets too late

About 21 percent of U.S. children between the ages of two and 19 have obesity, according to data from the Centers for Disease Control and Prevention

The Independent UK

Pfizer CFO Dave Denton to leave company in August

Pfizer's finance chief Dave Denton is leaving on August 15. Cecile Guegan will be the interim chief financial officer. Denton's departure raises investor concerns about Pfizer's 2026 forecast and succession plans. The company is preparing to enter the obesity drug market. Pfizer's shares were down in early trading. A search…

The Economic Times

From analysis to the latest developments in health,
read the most diverse news in one place.

Not all skinny: The French do get fat

With the French healthcare system now reimbursing the anti-obesity drugs Wegovy and Mounjaro, we explain what the strict conditions are to benefit from them. We discuss France's rates of obesity and the areas where they're highest. Finally, we discuss the common stereotype that French people don't get fat. While not…

France 24

GLP-1 Users Walk 560 Fewer Steps Per Day After Starting Ozempic or Wegovy, Fitbit Study Presented at ENDO 2026 Finds

ENDO 2026 study of 753 GLP-1 users found steps dropped 560/day and exercise fell 6 min/day after starting Ozempic or Wegovy. Muscle loss risk is the concern.

Medical Daily

India makes gains in child, maternal health but nutrition challenges persist: SBI report

India's latest health survey reveals significant improvements in maternal care and child vaccination rates. Stunting among children has seen a notable decline. However, modest gains in underweight and wasting indicate a need for comprehensive nutrition strategies. The survey also points to a rise in obesity among women. Fertility rates are…

The Economic Times

GLP-1 Drugs Like Ozempic Are Showing a 47 Percent Reduction in Breast Cancer Risk in a Major New Study — and Weight Loss May Not Explain It

A study presented at ASCO 2026 and published June 10, 2026 found that GLP-1 receptor agonists (semaglutide, tirzepatide) are associated with a 30–47% reduction in breast cancer risk among women with diabetes or obesity. The effect may operate through mechanisms beyond weight loss. Here is the full analysis.

Medical Daily

Read news from The Economist, FT, and more,
with one subscription

India risks becoming "unhealthier before it becomes richer," CEA V Anantha Nageswaran warns

India faces a health challenge before achieving wealth. Chief Economic Advisor V Anantha Nageswaran points to rising obesity and sedentary lifestyles. This impacts productivity and economic growth. He urges individuals to incorporate physical activity into daily routines. Improved health outcomes are seen as hidden growth potential for Viksit Bharat. This…

The Economic Times

Middle-aged adults taking GLP-1s for obesity can save $192K+ on lifetime medical costs, more if they don’t have college degrees, new study finds

The National Bureau of Economic Research paper's lead author hopes putting a dollar value on the benefits of GLP-1s will lead to better access

Fortune

India's weight-loss drug boom raises questions over healthcare priorities

India's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns about misuse for cosmetic reasons are growing. Regulators are intervening in advertising. The drugs also have side effects and can lead to weight regain. This boom is impacting pharmaceutical research priorities.

The Economic Times

UK approves Novo weight-loss pill to edge open European market

Britain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatment. Over 10 million people with obesity in the UK now have an alternative to injections. Drugmakers are racing to expand use of these transformative medicines. The market is expected…

The Economic Times

Wegovy weight-loss pills to be available for patients in UK to buy

Regulator approval means patients who meet criteria will be able to purchase tablets with private prescription

The Guardian - UK

Scientists Unveil a Diabetes and Obesity Pill That Burns Fat Through Muscle — Without Killing Your Appetite or Causing Muscle Loss

Karolinska/Stockholm University published a new obesity-diabetes pill in Cell (June 2026) that activates muscle metabolism to burn fat and lower blood sugar without appetite suppression or muscle loss. Safe in early human trial.

Medical Daily

First ever guidelines released to screen for condition that impacts 9 in 10 Americans

Doctors say earlier screening could help save lives

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

Medical Daily

Medicare Is About to Cover Weight-Loss Drugs for the First Time — Here's What the GLP-1 Bridge Program Means for Millions of Americans with Obesity

Medicare's GLP-1 Bridge launches July 1, 2026, offering eligible Part D enrollees Wegovy and Zepbound for $50/month — the first-ever Medicare coverage for obesity-specific GLP-1 drugs.

The Independent UK

New daily weight loss pill helps people shed 10 per cent of body weight

The pill doesn’t have the fasting requirements of many other weight loss drugs

MarketBeat

Corbus Pharmaceuticals Teases Cancer, Obesity Data as Key Clinical Readouts Near

Corbus Pharmaceuticals (NASDAQ:CRBP) Chief Executive Yuval Cohen outlined the company’s near-term clinical readout schedule and development plans for its two lead drug candidates during a Jefferies fireside chat hosted by biotech analyst Amin Makarem. Cohen said the Norwood, Massachusetts-based dru

The Independent UK

Why a dad bod isn’t as harmless as it seems

Approximately 100 million Americans live with obesity — a number that could more than double by 2050

Get all your
news in one place.

100's of premium titles.
One news app.

The Conversation

No, regaining weight after losing it won’t permanently damage your metabolism – new research

When it comes to losing weight, the fear of “ruining your metabolism” is widespread. Indeed, many people who have lost weight and then put it back on feel that every failed attempt leaves them worse off than before, with more fat, less muscle, greater hunger, lower energy, and an ever-diminishing…

The Economic Times

US stocks: Lilly shares rise on hopes that next-gen drug will extend lead in weight-loss market

Lilly presented full data from two retatrutide trials, one in treatment naive type 2 diabetes patients and another in patients ‌with obesity, ⁠at the ⁠American Diabetes Association meeting in New Orleans.

The Independent UK

Experts call for weight loss jabs to be investigated as cancer prevention

Experts from the US examined data on more than 161,000 patients

Medical Daily

Penn Medicine Reports 30% Drop in Breast Cancer Risk with Ozempic and Wegovy

Penn Medicine researchers report a 30% lower breast cancer risk in women using Ozempic and Wegovy, based on a study of 111,646 patients. Findings suggest GLP-1 drugs may play a role in cancer prevention, though experts stress results are observational.

The Economic Times

Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefits

Eli Lilly presented trial results for its new obesity drug retatrutide. The drug significantly reduced sleep apnea severity and knee osteoarthritis pain in adults with obesity. Patients also experienced substantial weight loss. These findings were shared at an American Diabetes Association conference. Retatrutide targets multiple hormones related to obesity and…

Medical Daily

Move Over, Ozempic: Scientists Unveiled a New Diabetes Pill That Burns Fat Without Killing Your Appetite — And It Could Be a Breakthrough for Millions of Americans

Researchers at Karolinska Institutet published a study showing a new oral compound activates muscle metabolism to lower blood sugar and torch fat — without nausea, muscle loss, or the side effects plaguing GLP-1 drugs.

Medical Daily

With Nation's Highest Diabetes Rate, San Antonio Faces Major Shift as Medicare Prepares $50 Wegovy Coverage

With diabetes rates among the highest in the U.S., San Antonio could see major change as Medicare's new $50 Wegovy coverage begins July 1, expanding access for eligible residents.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Centers for Disease Control and Prevention

228 stories

Novo

181 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.